Saudi Central Bank Buys 42,199 Shares of CVS Health Corporation $CVS

Key Points

• Saudi Central Bank increased its CVS Health stake by 15% in the second quarter, purchasing 42,199 additional shares and bringing its holdings to 324,060 shares valued at approximately $34.5 million.
• Analysts remain broadly positive on CVS, with 22 Buy ratings and two Holds; the stock carries a consensus “Moderate Buy” rating and an average price target of $106.83.
• CVS reported quarterly EPS of $2.58, exceeding expectations of $1.87, while revenue reached $106.1 billion, up 7.3% year over year. The company also maintains a quarterly dividend of $0.665 per share, equivalent to a 2.7% annual yield.

Saudi Central Bank increased its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 15.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 324,060 shares of the pharmacy operator's stock after purchasing an additional 42,199 shares during the quarter. Saudi Central Bank's holdings in CVS Health were worth $34,469,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the period. Swiss RE Ltd. bought a new position in shares of CVS Health in the fourth quarter valued at approximately $26,000. Kilter Group LLC purchased a new position in CVS Health during the second quarter valued at approximately $27,000. Sankala Group LLC purchased a new position in CVS Health during the fourth quarter valued at approximately $28,000. Finally, Global Trust Asset Management LLC increased its holdings in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after acquiring an additional 300 shares during the period. Hedge funds and other institutional investors own 80.66% of the company's stock.

Wall Street Analyst Weigh In

CVS has been the topic of several recent analyst reports. Mizuho raised their price target on CVS Health from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Monday, June 8th. Morgan Stanley upped their target price on CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a research note on Thursday, June 4th. TD Cowen lifted their price objective on CVS Health from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Royal Bank Of Canada lifted their price target on CVS Health from $107.00 to $113.00 and gave the stock an "outperform" rating in a research note on Thursday, July 9th. Finally, Piper Sandler reissued an "overweight" rating on shares of CVS Health in a research note on Wednesday, August 26th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.83.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $96.80 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The company has a 50-day moving average price of $100.79 and a 200-day moving average price of $90.14. The company has a market cap of $123.80 billion, a price-to-earnings ratio of 25.61, a price-to-earnings-growth ratio of 0.94 and a beta of 0.59. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health's quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. CVS Health's payout ratio is 70.37%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source